The effectiveness of TACE varies based on several factors, including tumor size, location, and liver function. Studies show that TACE can significantly prolong survival in patients with intermediate-stage HCC. However, it is generally not curative and is often used in combination with other treatments such as radiofrequency ablation or systemic therapies.
